Table 2.
Participant baseline demographic characteristics
| Characteristic | Study name | QP13C05 | QP13C14 | QP14C02 | QP14C11 | QP14C12 | QP14C21 | QP15C01 | QP15C05 | QP15C20* | QP16C04 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study drug | Piperaquine (N = 24) | Ferroquine (N = 8) | ACT-451840 (N = 8) | MMV390048 (N = 6) | OZ439 + DSM265 (N = 13) | Piperaquine (N = 6) | Cipargamin + piperaquine (N = 8) | Piperaquine + OZ439 or primaquine (N = 11) | SJ733 (N = 17) | MMV390048 (N = 15) | |
| Gender, n (%) | |||||||||||
| Male | 15 (62.5) | 3 (37.5) | 8 (100) | 6 (100) | 8 (61.5) | 2 (33.3) | 8 (100) | 11 (100) | 17 (100) | 15 (100) | |
| Female | 9 (37.5) | 5 (62.5) | 0 | 0 | 5 (38.5) | 4 (66.7) | 0 | 0 | 0 | 0 | |
| Mean age (SD) (years) | 22.9 (3.5) | 26.0 (6.4) | 24.1 (6.4) | 25.3 (4.0) | 26.1 (9.8) | 24.3 (4.7) | 27.9 (11.8) | 28.2 (9.8) | 26.6 (9.1) | 30.8 (9.0) | |
| Mean body weight (SD) (kg) | 68.1 (8.8) | 70.6 (9.1) | 77.2 (12.0) | 81.4 (16.6) | 72.0 (11.3) | 67.6 (19.8) | 79.4 (8.5) | 79.9 (12.8) | 80.7 (12.8) | 79.1 (14.3) | |
| Mean height (SD) (cm) | 172.7 (7.7) | 173.6 (6.6) | 178.8 (9.0) | 182.3 (7.5) | 173.0 (8.7) | 173.3 (12.9) | 177.8 (3.9) | 178.5 (9.0) | 179.4 (6.5) | 182.4 (6.6) | |
| Mean BMI (SD) (kg/m2) | 22.9 (2.5) | 23.3 (1.7) | 24.1 (2.9) | 24.5 (1.8) | 23.6 (2.6) | 22.0 (2.9) | 25.1 (2.7) | 25.0 (3.4) | 25.1 (3.8) | 23.7 (3.8) | |
| Race, n (%) | |||||||||||
| White | 20 (83.3) | 7 (87.5) | 4 (50.0) | 6 (100) | 12 (92.3) | 6 (100) | 4 (50.0) | 8 (72.7) | 1 (5.9) | 12 (80.0) | |
| Asian | 1 (4.2) | 1 (12.5) | 1 (12.5) | 0 | 0 | 0 | 0 | 0 | 15 (88.2) | 0 | |
| Other | 3 (12.5) | 0 | 3 (37.5) | 0 | 1 (7.7) | 0 | 4 (50.0) | 3 (27.3) | 1 (5.9) | 3 (20.0) | |
BMI = body mass index.
*
Two participants did not receive the new chemical entity dose and were not included in the analysis.